Prospective study of an orally-active ghrelin receptor agonist in patients with unresectable pancreatic cancer and cachexia

Prospective study of an orally-active ghrelin receptor agonist in patients with unresectable pancreatic cancer and cachexia - Prospective study of an orally-active ghrelin receptor agonist in patients with unresectable pancreatic cancer and cachexia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044724

Enrollment

150

Registered

2021-07-01

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. the patients with chemotherapy for unresectable pancreatic cancer 2. the patients with selective ghrelin receptor agonist for cachexia 3. age>= 20 years

Exclusion criteria

Exclusion criteria: 1. Judgement by doctors 2. Off label use for selective ghrelin receptor agonist

Design outcomes

Primary

Measure	Time frame
Change in the body weight from the baseline over the 12-week treatment period	—

Secondary

Measure	Time frame
1. the changes in visceral fat and subcutaneous fat 2. adverse events of selective agonist of the ghrelin receptor 3. treatment periods of selective agonist of the ghrelin receptor 4. Progression free survival of chemotherapy 5. Overall survival of chemotherapy 6. Tumor response rate 7. Disease control rate 8. Adverse events of chemotherapy 9. QOL assessment	—

Countries

Japan

Contacts

Public ContactTatsunori Suzuki

Graduate School of Medicine, The University of Tokyo Department of Gastroenterology

suzutatsu86@gmail.com03-3815-5411

Outcome results